GlobeNewswire Inc.··Immunocore Holdings PlcImmunocore's KIMMTRAK Doubles Five-Year Survival Rate, Posts 14% Revenue Growth
Immunocore reports $106.7M Q1 KIMMTRAK sales, up 14% YoY, with landmark data showing doubled five-year survival in uveal melanoma patients.
IMCRPhase 3 trialimmunotherapy